,8, 9, 10, 11, 12 Cardiac biomarkers, such as high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been used for risk stratification of cardiovascular toxicity before initiating anticancer therapy and for monitoring cardiovascular complications during treatment.13, 14, 15, 16 Elevated levels of these cardiac biomarkers and cardiac dysfunction are frequently associated with increased cardiac events and mortality in cancer patients.17, 18, 19, 20. Here, TNNT2 is linked to cancer.